Inicio>>MKI-1

MKI-1 (Synonyms: MASTL Kinase Inhibitor-1)

Catalog No.GC62348

MKI-1, un inhibidor de MASTL (similar a la serina/treonina quinasa asociada a microtÚbulos) con una IC50 de 9,9 μM, ejerce actividades antitumorales y radiosensibilizadoras a través de la activaciÓn de PP2A en el cÁncer de mama.

Products are for research use only. Not for human use. We do not sell to patients.

MKI-1 Chemical Structure

Cas No.: 1190277-80-5

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
297,00 $
Disponible
5 mg
270,00 $
Disponible
10 mg
450,00 $
Disponible
25 mg
855,00 $
Disponible
50 mg
1.395,00 $
Disponible
100 mg
2.115,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer[1].

MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells[1].MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells[1].MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation[1].MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells[1].

MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice[1].

[1]. Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10:571601.

Reseñas

Review for MKI-1

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MKI-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.